Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational, retrospective, multicenter study to assess the efficacy of fingolimod in clinical practice in patients with relapsing-remitting multiple sclerosis

Next Previous
Trial Profile

An observational, retrospective, multicenter study to assess the efficacy of fingolimod in clinical practice in patients with relapsing-remitting multiple sclerosis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms NEXT

Most Recent Events

  • 27 Jun 2017 Results (n=988) of a pooled analysis of two observational retrospective studies MS SECOND LINE GATE and MS NEXT assessing basal characteristics and effectiveness of fingolimod, presented at the 3rd Congress of the European Academy of Neurology
  • 28 Apr 2017 Results (n=988) of a pooled analysis of two observational retrospective studies (MS SECOND LINE GATE and MS NEXT) assessing safety and tolerability of fingolimod in Spanish clinical practice, presented at the 69th Annual Meeting of the American Academy of Neurology
  • 28 Apr 2017 Results of pooled analysis of two observational retrospective studies (MS SECOND LINE GATE and MS NEXT) presented at the 69th Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top